Molecular targets for anti-oxidative protection of green tea polyphenols against myocardial ischemic injury

BioMedicine (Taiwan)

Volumn 4, Issue 4, 2014, Pages 7-16

  Hsieh, Shih Rong ^b   Cheng, Wei Chen ^c   Su, Yi Min ^a   Chiu, Chun Hwei ^a   Liou, Ying Ming ^a  

^a NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

^b TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^c NATIONAL TSING HUA UNIVERSITY   (Taiwan)

Author keywords

Cardio protection; Green tea polyphenols (GTPs); Ischemic heart disease; Oxidative stress; Proteomics

Indexed keywords

ANTIOXIDANT; G PROTEIN COUPLED RECEPTOR; GLYCOGEN SYNTHASE KINASE 3BETA; POLYPHENOL DERIVATIVE;

ADAPTATION; CAVEOLA; HEART MUSCLE INJURY; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; ISCHEMIC PRECONDITIONING; LIPID RAFT; MYOBLAST; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEOMICS; REVIEW; SIGNAL TRANSDUCTION; TEA;

EID: 84939516369     PISSN: 22118020     EISSN: 22118039     Source Type: Journal    
DOI: 10.7603/s40681-014-0023-0     Document Type: Review

References (85)

1. Mak JC. Potential role of green tea catechins in various disease therapies: Progress and promise. Clin Exp Pharmacol Physiol 2012; 39: 265-73.
2. Liou YM, Hsieh SR, Wu TJ. Green tea and cardiac health. CAB Reviews: Perspectives in Agriculture, Veterinary Science, Nutrition and Natural Resources. 2009; 4: 020.
3. Jochmann N, Baumann G, Stangl V. Green tea and cardiovascular disease: from molecular targets towards human health. Curr Opin Clin Nutr Metab Care 2008; 11: 758-65.
4. Wolfram S. Effects of green tea and EGCG on cardiovascular and metabolic health. J Am Coll Nutr 2007; 26: 373S-88S.
5. Stangl V, Dreger H, Stangl K, Lorenz M. Molecular targets of tea polyphenols in the cardiovascular system. Cardiovasc Res 2007; 73: 348-58.
6. Sumpio BE, Cordova AC, Berke-Schlessel DW, Qin F, Chen QH. Green tea, the "Asian paradox, " and cardiovascular disease. J Am Coll Surg 2006; 202: 813-25.
7. Stangl V, Lorenz M, Stangl K. The role of tea and tea flavonoids in cardiovascular health. Mol Nutr Food Res 2006; 50: 218-28.
8. Kuriyama S. The relation between green tea consumption and cardiovascular disease as evidenced by epidemiological studies. J Nutr 2008; 138: 1548S-53S.
9. Kuriyama S, Shimazu T, Ohmori K, Kikuchi N, Nakaya N, Nishino Y, et al. Green tea consumption and mortality due to cardiovascular disease, cancer, and all causes in Japan: the Ohsaki study. JAMA 2006; 296: 1255-65.
10. Mukamal KJ, Maclure M, Muller JE, Sherwood JB, Mittleman MA. Tea consumption and mortality after acute myocardial infarction. Circulation 2002; 105: 2476-81.
11. Hirano R, Momiyama Y, Takahashi R, Taniguchi H, Kondo K, Nakamura H, et al. Comparison of green tea intake in Japanese patients with and without angiographic coronary artery disease. Am J Cardio 2002; 90: 1150-53.
12. Peters U, Poole C, Arab L. Does tea affect cardiovascular disease? A meta-analysis. Am J Epidemiol 2001; 154: 495-503.
13. Liou YM, Hsieh SR, Wu TJ, Chen JY. Green tea extract given before regional myocardial ischemia-reperfusion in rats improves myocardial contractility by attenuating calcium overload. Pflugers Arch 2010; 460: 1003-14.
14. Shieh SR, Tsai DC, Chen JY, Tsai SW, Liou YM. Green tea extract protects rats against myocardial infarction associated with left anterior descending coronary artery ligation. Pflugers Arch 2009; 458: 631-642.
15. Dreger H, Lorenz M, Kehrer A, Baumann G, Stangl K, Stangl V. Characteristics of catechin- and theaflavin-mediated cardioprotection. Exp Biol Med (Maywood) 2008; 233: 427-33.
16. Li D, Yang C, Chen Y. Identification of a PKC-dependent regulation of myocardial contraction by epicatechin-3-gallate. Am J Physiol Heart Circ Physiol 2008; 294: H345-H53.
17. Liou YM, Kuo SC, Hsieh SR. Differential effects of a green teaderived polyphenol (-)-epigallocatechin-3-gallate on the acidosis-induced decrease in the Ca2+ sensitivity of cardiac and skeletal muscle. Pflugers Arch 2008; 456: 787-800.
18. Lorenz M, Hellige N, Rieder P. Positive inotropic effects of epigallocatechin- 3-gallate (EGCG) involve activation of Na+/H+ and Na+/ Ca2+ exchangers. Eur J Heart Fail 2008; 10: 439-45.
19. Hirai M, Hotta Y, Ishikawa N, Wakida Y, Fukuzawa Y, Isobe F, et al. Protective effects of EGCg or GCg, a green tea catechin epimer, against postischemic myocardial dysfunction in guinea-pig hearts. Life Sci 2007; 80: 1020-32.
20. Townsend PA, Scarabelli TM, Pasini E, Gitti G, Menegazzi M, Suzuki H, et al. Epigallocatechin-3-gallate inhibits STAT-1 activation and protects cardiac myocytes from ischemia/reperfusion-induced apoptosis. FASEB J 2004; 18: 1621-23.
21. Nakagawa T, Yokozawa T. Direct scavenging of nitric oxide and superoxide by green tea. Food Chem Toxicol 2002; 40: 1745-50.
22. Santos CX, Anilkumar N, Zhang M, Brewer AC, Shah AM. Redox signaling in cardiac myocytes. Free Radic Biol Med 2011; 50: 777-93.
23. Wall SB, Oh JY, Diers AR, Landar A. Oxidative modification of proteins: an emerging mechanism of cell signaling. Front Physiol 2012; 3: 369.
24. Frei B, Higdon JV. Antioxidant activity of tea polyphenols in vivo: evidence from animal studies. J Nutr 2003; 133: 3275-84.
25. Wu CC, Hsu MC, Hsieh CW, Lin JB, Lai PH, Wung BS. Upregulation of heme-oxygenase-1 by epigallocatechin-3-gallate via the phosphatidylinositol 3-kinase/Akt and ERK pathways. Life Sci 2006; 78: 2889-97.
26. Rice-Evans CA, Miller NJ, Paganga G. Structure-antioxidant activity relationships of flavonoids and phenolic acids. Free Radic Biol Med 1996; 20: 933-56.
27. Beecher GR. Overview of dietary flavonoids: nomenclature, occurrence and intake. J Nutr 2003; 133: 3248S-54S.
28. Graham HN. Green tea composition, consumption, and polyphenol chemistry. Prev Med 1992; 21: 334-50.
29. Chen WC, Hsieh SR, Chiu CH, Hsu BD, Liou YM. Molecular identification for epigallocatechin-3-gallate-mediated antioxidant intervention on the H2O2-induced oxidative stress in H9c2 rat cardiomyoblasts. J Biomed Sci 2014; 21: 56.
30. Hsieh SR, Hsu CS, Lu CH, Chen WC, Chiu CH, Liou YM. Epigallocatechin- 3- gallate- mediated cardioprotection by Akt/GSK-3/caveolin signalling in H9c2 rat cardiomyoblasts. J Biomed Sci 2013; 20: 86.
31. Sheng R, Gu ZL, Xie ML, Zhou WX, Guo CY. Epigallocatechin gallate protects H9c2 cardiomyoblasts against hydrogen dioxidesinduced apoptosis and telomere attrition. Eur J Pharmacol 2010; 641: 199-206.
32. Kumar D, Jugdutt BI. Apoptosis and oxidants in the heart. J Lab Clin Med 2003; 142: 288-97.
33. Anversa P, Cheng W, Liu Y, Leri A, Redaelli G, Kajstura J. Apoptosis and myocardial infarction. Basic Res Cardiol 1998; 93, Suppl 3: 8-12.
34. Anversa P, Kajstura J. Myocyte cell death in the diseased heart. Circ Res 1998; 82: 1231-33.
35. Anversa P, Olivetti G, Leri A, Liu Y, Kajstura J. Myocyte cell death and ventricular remodeling. Curr Opin Nephrol Hypertens 1997; 6: 169-76.
36. Murphy E, Steenbergen C. Mechanisms underlying acute protection from cardiac ischemia-reperfusion injury. Physiol Rev 2008; 88: 581-609.
37. Ferdinandy P, Schulz R, Baxter GF. Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and postconditioning. Pharmacol Rev 2007; 59: 418-58.
38. Corbucci GG, Perrino C, Donato G, Ricchi A, Lettieri B, Troncone G, et al. Transient and reversible deoxyribonucleic acid damage in human left ventricle under controlled ischemia and reperfusion. J Am Coll Cardiol 2004; 43: 1992-99.
39. Bolli R, Marbán E. Molecular and cellular mechanisms of myocardial stunning. Physiol Rev 1999; 79: 609-34.
40. Heyndrickx GR, Millard RW, McRitchie RJ, Maroko PR, Vatner SF. Regional myocardial functional and electrophysiological alterations after brief coronary artery occlusion in conscious dogs. J Clin Invest 1975; 56: 978-85.
41. Depre C, Vatner SF. Cardioprotection in stunned and hibernating myocardium. Heart Fail Rev 2007; 12: 307-317.
42. McCully JD, Wakiyama H, Hsieh YJ, Jones M, Levitsky S. Differential contribution of necrosis and apoptosis in myocardial ischemia/ reperfusion injury. Am J Physiol Heart Circ Physiol 2004; 286: H1923-35.
43. Koerner JE, Anderson BA, Dage RC. Protection against postischemic myocardial dysfunction in anesthetized rabbits with scavengers of oxygen-derived free radicals: superoxide dismutase plus catalase, N-2-mercaptopropionyl glycine and captopril. J Cardiovasc Pharmacol 1991; 17: 185-91.
44. Hausenloy DJ, Yellon DM. Survival kinases in ischemic preconditioning and postconditioning. Cardiovasc Res 2006; 70: 240-53.
45. Pain T, Yang XM, Critz SD, Yue Y, Nakano A, Liu GS, et al. Opening of mitochondrial K(ATP) channels triggers the preconditioned state by generating free radicals. Circ Res 2000; 87: 460-66.
46. Miwa S, Yamazaki K, Hyon SH, Komeda M. A novel method of 'preparative' myocardial protection using green tea polyphenol in oral uptake. Interact Cardiovasc Thorac Surg 2004; 3: 612-5.
47. Hori M, Nishida K. Oxidative stress and left ventricular remodelling after myocardial infarction. Cardiovasc Res 2009; 81: 457-64.
48. Baines CP, Goto M, Downey JM. Oxygen radicals released during ischemic preconditioning contribute to cardioprotection in the rabbit myocardium. J Mol Cell Cardiol 1997; 29: 207-16.
49. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 1986; 74: 1124-36.
50. Fryer RM, Schultz JEJ, Hsu AK, Gross GJ. Importance of PKC and tyrosine kinase in single or multiple cycles of preconditioning in rat hearts. Am J Physiol Heart Circ Physiol 1999; 276: H1229-35.
51. Pagliaro P, Gattullo D, Rastaldo R, Losano G. Ischemic preconditioning: from the first to the second window of protection. Life Sci 2001; 69: 1-15.
52. Juhaszova M, Zorov DB, Kim SH, Pepe S, Fu Q, Fishbein KW, et al. Glycogen synthase kinase-3beta mediates convergence of protection signaling to inhibit the mitochondrial permeability transition pore. J Clin Invest 2004; 113: 1535-49.
53. Kukkonen JP. A mnagetrois made in heaven: G-protein-coupled receptors, lipids and TRP channels. Cell Calcium 2011; 50: 9-26.
54. Allen JA, Halverson-Tamboli RA, Rasenick MM. Lipid raft microdomains and neurotransmitter signaling. Nat Rev Neurosci 2007; 8: 128-40.
55. Simons K, Ikonen E. Functional rafts in cell membranes. Nature 1997; 387: 569-72.
56. Chichili G, Rodgers W. Cytoskeleton-membrane interactions in membrane raft structure. Cell Mol Life Sci 2009; 66: 2319-28.
57. Head BP, Patel HH, Roth DM, Murray F, Swaney JS, Niesman IR, et al. Microtubules and actin microfilaments regulate lipid raft/ caveolae localization of adenylyl cyclase signaling components. J Biol Chem 2006; 281: 26391-9.
58. Li PL, Zhang Y, Yi F. Lipid raft redox signaling platforms in endothelial dysfunction. Antioxid Redox Signal 2007; 9: 1457-70.
59. Das M, Das DK. Lipid Raft in Cardiac Health and Disease. Curr Cardiol Rev 2009; 5: 105-11.
60. Michel V, Bakovic M. Lipid rafts in health and disease. Biol Cell 2007; 99: 129-40.
61. Jin S, Zhou F, Katirai F, Li PL. Lipid raft redox signaling: molecular mechanisms in health and disease. Antioxid Redox Signal 2011; 15: 1043-83.
62. Horikawa YT, Patel HH, Tsutsumi YM, Jennings MM, Kidd MW, Hagiwara Y, et al. Caveolin-3 expression and caveolae are required for isoflurane induced cardiac protection from hypoxia and ischemia/ reperfusion injury. J Mol Cell Cardiol 2008; 44: 123-30.
63. Patel HH, Tsutsumi YM, Head BP, Niesman IR, Jennings M, Horikawa Y, et al. Mechanisms of cardiac protection from ischemia/reperfusion injury: a role for caveolae and caveolin-1. FASEB J 2007; 21: 1565-74.
64. Rapacciuolo A, Suvarna S, Barki-Harrington L, Luttrell LM, Cong M, Lefkowitz RJ, et al. Protein kinase A and G protein-coupled receptor kinase phosphorylation mediates beta-1 adrenergic receptor endocytosis through different pathways. J Biol Chem 2003; 278: 35403-11.
65. Steinberg SF. β2-Adrenergic receptor signaling complexes in cardiomyocyte caveolae/lipid rafts. J Mol Cell Cardiol 2004; 37: 407-15.
66. Juhaszova M, Zorov DB, Yaniv Y, Nuss HB, Wang S, Sollott SJ. Role of glycogen synthase kinase-3beta in cardioprotection. Circ Res 2009; 104: 1240-52.
67. Omar MA, Wang L, Clanachan AS. Cardioprotection by GSK-3 inhibition: role of enhanced glycogen synthesis and attenuation of calcium overload. Cardiovasc Res 2010; 86: 478-86.
68. Vigneron F, Dos Santos P, Lemoine S, Bonnet M, Tariosse L, Couffinhal T, Dupla? C, Jaspard-Vinassa B. GSK-3β at the crossroads in the signalling of heart preconditioning: implication of mTOR and Wnt pathways. Cardiovasc Res 2011; 90: 49-56.
69. Takahashi-Yanaga F, Sasaguri T. GSK-3beta regulates cyclin D1 expression: a new target for chemotherapy. Cell Signal 2008; 20: 581-9.
70. Dohn MR, Brown MV, Reynolds AB. An essential role for p120- catenin in Src- and Rac1-mediated anchorage-independent cell growth. J Cell Biol 2009; 184: 437-50.
71. Huelsken J, Birchmeier W. New aspects of Wnt signaling pathways in higher vertebrates. Curr Opin Genet Dev 2001; 11: 547-53.
72. Daugherty RL, Gottardi CJ. Phospho-regulation of Beta-catenin adhesion and signaling functions. Physiology 2007; 22: 303-9.
73. Dashwood WM, Carter O, Al-Fageeh M, Li Q, Dashwood RH. Lysosomal trafficking of beta-catenin induced by the tea polyphenol epigallocatechin-3-gallate. Mutat Res 2005; 591: 161-72.
74. Guo Y, Fu Z, Van Eyk J. A Proteomic Primer for the Clinician. Proc Am Thorac Soc 2007; 4: 9-17.
75. McGregor E, Dunn MJ. Proteomics of the Heart: Unraveling Disease. Circ Res 2006; 98: 309-21.
76. Arab S, Gramolini AO, Ping P, Kislinger T, Stanley B, van Eyk J, et al. Cardiovascular Proteomics: Tools to Develop Novel Biomarkers and Potential Applications. J Am Coll Cardiol 2006; 48: 1733-41.
77. Scobioala S, Klocke R, Kuhlmann M, Tian W, Hasib L, Milting H, et al. Up-regulation of nestin in the infarcted myocardium potentially indicates differentiation of resident cardiac stem cells into various lineages including cardiomyocytes. FASEB J 2009-8; 22: 1021-31.
78. Mateos-Cáceres PJ, García-M?ndez A, Farr? AL, Macaya C, Núñez A, Gómez J, et al. Proteomic analysis of plasma from patients during an acute coronary syndrome. J Am Coll Cardiol 2004; 44: 1578-83.
79. Buerke B, Schwertz H, L?ngin T, Buerke U, Prondzinsky R, Platsch H, et al. Proteome analysis of myocardial tissue following ischemia and reperfusion-Effects of complement inhibition. Biochimica et Biophysica Acta 2006; 1764: 1536-45.
80. Sawicki G, Jugdutt BI. Detection of regional changes in protein levels in the in vivo canine model of acute heart failure following ischemia-reperfusion injury: functional proteomics studies. Proteomics 2004; 4: 2195-2202.
81. Schwertz H, Langin T, Platsch H, Richert J, Bomm S, Schmidt M, et al. Two-dimensional analysis of myocardial protein expression following myocardial ischemia and reperfusion in rabbits. Proteomics 2002; 2: 988-95.
82. Chen CY, Lee BC, Hsu HC, Lin HJ, Chao CL, Lin YH, et al. A proteomic study of the effects of ramipril on post-infarction left ventricular remodelling in the rabbit. Euro J Heart Fail 2008; 10: 740-8.
83. Sakai J, Ishikawa H, Kojima S, Satoh H, Yamamoto S, Kanaoka M. Proteomic analysis of rat heart in ischemia and ischemia-reperfusion using fluorescence two-dimensional difference gel electrophoresis. Proteomics 2003; 3: 1318-24.
84. De Celle T, Vanrobaeys F, Lijnen P, Blankesteijn WM, Heeneman S, Van Beeumen J, et al. Alterations in mouse cardiac proteome after in vivo myocardial infarction: permanent ischaemia versus ischaemia- reperfusion. Exp Physiol 2005; 90: 593-606.
85. Chou HC, Chen YW, Lee TR, Wu FS, Chan HT, Lyu PC, et al. Proteomics study of oxidative stress and Src kinase inhibition in H9c2 cardiomyocytes: a cell model of heart ischemia-reperfusion injury and treatment. Free Radic Biol Med 2010; 49: 96-108.